{"id":"NCT00312494","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects","officialTitle":"A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2006-04-10","resultsPosted":"2010-01-22","lastUpdate":"2021-03-29"},"enrollment":680,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Ziprasidone","otherNames":["Geodon, Zeldox"]},{"type":"DRUG","name":"Ziprasidone","otherNames":["Geodon, Zeldox"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Ziprasidone 20-40mg twice a day (BID)","type":"EXPERIMENTAL"},{"label":"Ziprasidone 60-80mg BID","type":"EXPERIMENTAL"}],"summary":"3-week study to evaluate efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects","primaryOutcome":{"measure":"Change From Baseline to Week 3 in Young Mania Rating Scale (YMRS)","timeFrame":"Baseline, Week 3","effectByArm":[{"arm":"Ziprasidone (Higher Dose)","deltaMin":-10.19,"sd":0.78},{"arm":"Ziprasidone (Lower Dose)","deltaMin":-10.95,"sd":0.8},{"arm":"Placebo","deltaMin":-9.47,"sd":0.83}],"pValues":[{"comp":"OG001 vs OG002","p":"0.1077"},{"comp":"OG000 vs OG002","p":"0.4274"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":66,"countries":["United States"]},"refs":{"pmids":["23218158","23218157"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281143&StudyName=3-week%20study%20to%20evaluate%20efficacy%20and%20safety%20of%20ziprasidone%20with%20either%20lithium%20or%20divalproex%20in%20acutely%20manic%20subjects"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":223},"commonTop":["Sedation","Somnolence","Headache","Nausea","Diarrhoea"]}}